Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)

Background The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients. Methods We collected data of patients from 30 MS centres across the country starting Sativex between January 2014 and February 2015. Data were collected from the mandatory Italian Medicines Agency (AIFA) web-registry. Predictors of treatment discontinuation were assessed using a multivariate Cox proportional regression analysis. Results During the observation period 631 out of 1597 (39.5%) patients discontinued Sativex. The Kaplan-Meier estimates curve showed that 333 patients (20.8%) discontinued treatment at 4 weeks while 422 patients (26.4%) discontinued at 6 weeks. We found after adjusted modeling that a higher NRS score at T1 (adjHR 2.23, 95% 2.07–2.41, p<0.001) and a lower baseline NRS score (adjHR 0.51 95% CI 0.46–0.56, p<0.001) were predictive of treatment discontinuation. Conclusion These data show that the first 6 weeks are useful in identifying those patients in which Sativex could be effective, thus avoiding the cost of longer term evaluation.

[1]  J. Slof,et al.  Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy , 2015, Expert review of pharmacoeconomics & outcomes research.

[2]  C. Collin,et al.  A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.

[3]  C. Vila,et al.  Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study , 2011, Expert review of pharmacoeconomics & outcomes research.

[4]  N. Vasilyev,et al.  New data on , 1970 .

[5]  Carlo Pozzilli,et al.  Overview of MS Spasticity , 2014, European Neurology.

[6]  U. Zettl,et al.  Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity , 2014, European Neurology.

[7]  J. Wight,et al.  Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.

[8]  U. Zettl,et al.  Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice , 2014, European Neurology.

[9]  D. Wade,et al.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.

[10]  G. Izquierdo Multiple sclerosis symptoms and spasticity management: new data. , 2017, Neurodegenerative disease management.

[11]  A. Thompson,et al.  Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper , 2016, Multiple sclerosis.

[12]  C. Young,et al.  Anti-spasticity agents for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.

[13]  F. Patti,et al.  Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey , 2014, Neuroepidemiology.

[14]  S. Meuth,et al.  Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis , 2015, Expert review of neurotherapeutics.

[15]  I. Lang,et al.  Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis , 2012, PharmacoEconomics.

[16]  J. Farrar,et al.  Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.

[17]  P. Vermersch MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. , 2014, Neurodegenerative disease management.

[18]  C. Collin,et al.  Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis , 2012, Journal of Neurology.

[19]  D. Centonze,et al.  Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  J. Slof,et al.  Sativex® in multiple sclerosis spasticity: a cost–effectiveness model , 2012, Expert review of pharmacoeconomics & outcomes research.

[21]  P. Flachenecker Evolution of multiple sclerosis spasticity-associated symptoms: latest data. , 2016, Neurodegenerative disease management.

[22]  C. Pozzilli,et al.  A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.

[23]  D. Wade,et al.  Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis , 2006, Multiple sclerosis.

[24]  C. Collin,et al.  Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European journal of neurology.

[25]  Andrew Briggs,et al.  Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  C. Vila,et al.  Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. , 2014, Journal of comparative effectiveness research.

[27]  C. Oreja-Guevara,et al.  Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity , 2015 .

[28]  A. García-Merino,et al.  Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis , 2014, Expert review of neurotherapeutics.